Compare KKR & Co Inc (KKR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Recursion Pharmaceuticals Inc — how do they compare? KKR & Co Inc trades at $110.7 (market cap $99.61B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: KKR & Co Inc is far larger — about 55× Recursion Pharmaceuticals Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| KKR | RXRX | |
|---|---|---|
Market Cap | $99.61B | $1.81B |
Sector | Financials | Health |
52-Week High | $149.34 | $6.79 |
52-Week Low | $83.88 | $2.84 |
Enterprise Value | $22.17B | $1.33B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR's stock trades at $110.37, up 6.3% today, showing strong momentum near recent highs. The technical outlook is bullish with the price above key moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.63, beating estimates of $1.43, with revenue growth supported by recent acquisitions including Integer Holdings and Medicover India. Analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $127.22 consensus price target.
KKR presents a compelling investment case with strong earnings momentum, strategic acquisitions expanding its healthcare and infrastructure portfolios, and robust analyst support. However, risks include execution challenges from recent M&A activity, potential market volatility affecting asset valuations, and the stock's current premium valuation multiples. The company's ability to integrate acquisitions and maintain fundraising momentum will be key drivers of future performance.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
